1 January 2021
EMA/652257/2020
EMEA/H/C/000279

Public statement

Panretin (SRD)

Withdrawal of the marketing authorisation in the European Union

On 1 January 2021, the European Commission withdrew the marketing authorisation for Panretin (SRD) (alitretinoin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amdipharm Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Panretin (SRD) was granted marketing authorisation in the EU on 11 October 2000 for treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS). The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for Panretin (SRD) will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union